Postoperative angiotensin II receptor blocker use is associated with reduced 2-year reoperation rates in male patients undergoing arthroscopic rotator cuff repair

Q2 Medicine
Scott Fong BA , Nicholas J. Pettinelli MS , Michael S. Lee BS , James S. Macleod BS , Stephen M. Gillinov AB , Peter F. Monahan BS , Jay Moran MD , Anshu Jonnalagadda BS , Ronak J. Mahatme BS , John M. Apostolakos MD, MPH , Andrew E. Jimenez MD
{"title":"Postoperative angiotensin II receptor blocker use is associated with reduced 2-year reoperation rates in male patients undergoing arthroscopic rotator cuff repair","authors":"Scott Fong BA ,&nbsp;Nicholas J. Pettinelli MS ,&nbsp;Michael S. Lee BS ,&nbsp;James S. Macleod BS ,&nbsp;Stephen M. Gillinov AB ,&nbsp;Peter F. Monahan BS ,&nbsp;Jay Moran MD ,&nbsp;Anshu Jonnalagadda BS ,&nbsp;Ronak J. Mahatme BS ,&nbsp;John M. Apostolakos MD, MPH ,&nbsp;Andrew E. Jimenez MD","doi":"10.1016/j.jseint.2025.05.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Angiotensin II receptor blockers (ARBs) antagonize the effects of transforming growth factor-β1, a cytokine mediator for fibrosis and fatty infiltration in skeletal muscle. The objective of this study was to determine (1) if postoperative ARB use is associated with reduced rates of secondary surgery 2 years following arthroscopic rotator cuff repair, and (2) whether there are differences in these outcomes within male-, female-, and non–sex-specific cohorts.</div></div><div><h3>Methods</h3><div>The TriNet X national database was queried to identify patients between 2015 and 2022 who were prescribed an ARB (losartan, valsartan, or olmesartan) within 3 months of arthroscopic rotator cuff repair. ARB patients were propensity matched 1:1 with a non-ARB control. Analyses were conducted to assess outcomes differences within male-, female-, and non–sex-specific cohorts. Two-year secondary surgery rates (manipulation under anesthesia, revision rotator cuff repair, conversion to reverse or anatomic total shoulder arthroplasty, and non-rotator cuff repair arthroscopic shoulder procedures) were evaluated and compared using odds ratios (OR).</div></div><div><h3>Results</h3><div>In total, 2,883 matched ARB and non-ARB rotator cuff repair patients were included, with a mean age of 62.5 years, and 42% female in each cohort. In the non–sex-specific analysis, within 2 years after surgery, the non-ARB cohort had similar rates of revision rotator cuff repair as the control. In the female-specific analysis, 1,228 matched ARB and non-ARB females were included, with an average age of 63.2 years, and there were no statistically significant differences in secondary surgery rates. In the male-specific analysis, 1,562 matched males were included, with an average of 62 years. The male non-ARB cohort reported significantly higher rates of undergoing revision rotator cuff repair (OR 1.33, 95% confidence interval [1.01-1.75], <em>P</em> = .039) and significantly higher rates of undergoing total non–rotator cuff repair arthroscopic shoulder procedures (OR 1.35, 95% [confidence interval] [1.04-1.75], <em>P</em> = .025) compared to the ARB male cohort.</div></div><div><h3>Conclusion</h3><div>The findings of this study suggest that ARB use may be associated with lower rates of secondary shoulder surgeries in patients undergoing rotator cuff repair, with the effects predominantly observed in male patients.</div></div>","PeriodicalId":34444,"journal":{"name":"JSES International","volume":"9 5","pages":"Pages 1517-1523"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JSES International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666638325001677","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Angiotensin II receptor blockers (ARBs) antagonize the effects of transforming growth factor-β1, a cytokine mediator for fibrosis and fatty infiltration in skeletal muscle. The objective of this study was to determine (1) if postoperative ARB use is associated with reduced rates of secondary surgery 2 years following arthroscopic rotator cuff repair, and (2) whether there are differences in these outcomes within male-, female-, and non–sex-specific cohorts.

Methods

The TriNet X national database was queried to identify patients between 2015 and 2022 who were prescribed an ARB (losartan, valsartan, or olmesartan) within 3 months of arthroscopic rotator cuff repair. ARB patients were propensity matched 1:1 with a non-ARB control. Analyses were conducted to assess outcomes differences within male-, female-, and non–sex-specific cohorts. Two-year secondary surgery rates (manipulation under anesthesia, revision rotator cuff repair, conversion to reverse or anatomic total shoulder arthroplasty, and non-rotator cuff repair arthroscopic shoulder procedures) were evaluated and compared using odds ratios (OR).

Results

In total, 2,883 matched ARB and non-ARB rotator cuff repair patients were included, with a mean age of 62.5 years, and 42% female in each cohort. In the non–sex-specific analysis, within 2 years after surgery, the non-ARB cohort had similar rates of revision rotator cuff repair as the control. In the female-specific analysis, 1,228 matched ARB and non-ARB females were included, with an average age of 63.2 years, and there were no statistically significant differences in secondary surgery rates. In the male-specific analysis, 1,562 matched males were included, with an average of 62 years. The male non-ARB cohort reported significantly higher rates of undergoing revision rotator cuff repair (OR 1.33, 95% confidence interval [1.01-1.75], P = .039) and significantly higher rates of undergoing total non–rotator cuff repair arthroscopic shoulder procedures (OR 1.35, 95% [confidence interval] [1.04-1.75], P = .025) compared to the ARB male cohort.

Conclusion

The findings of this study suggest that ARB use may be associated with lower rates of secondary shoulder surgeries in patients undergoing rotator cuff repair, with the effects predominantly observed in male patients.
术后使用血管紧张素受体阻滞剂可降低接受关节镜下肩袖修复的男性患者2年再手术率
血管紧张素II受体阻断剂(ARBs)可拮抗骨骼肌纤维化和脂肪浸润的细胞因子转化生长因子-β1的作用。本研究的目的是确定(1)术后使用ARB是否与关节镜下肩袖修复术后2年的二次手术发生率降低有关,以及(2)这些结果在男性、女性和非性别特异性队列中是否存在差异。方法查询TriNet X国家数据库,以确定2015年至2022年期间在关节镜下肩袖修复术3个月内服用ARB(氯沙坦、缬沙坦或奥美沙坦)的患者。ARB患者与非ARB对照组倾向匹配为1:1。进行分析以评估男性、女性和非性别特异性队列的结果差异。使用比值比(or)评估并比较2年的二次手术率(麻醉下操作、肩袖翻修修复、转为反向或解剖性全肩关节置换术以及关节镜下的非肩袖修复手术)。结果共纳入2,883例匹配的ARB和非ARB肩袖修复患者,平均年龄为62.5岁,每个队列中42%为女性。在非性别特异性分析中,术后2年内,非arb组的肩袖修复率与对照组相似。在女性特异性分析中,纳入1228例匹配ARB和非ARB的女性,平均年龄为63.2岁,二次手术率差异无统计学意义。在男性特异性分析中,包括1562名匹配的男性,平均年龄为62岁。与男性ARB组相比,男性非ARB组接受肩袖修复翻修的比例显著高于男性ARB组(OR 1.33, 95%可信区间[1.01-1.75],P = 0.039),接受关节镜肩关节手术的全非肩袖修复的比例显著高于男性ARB组(OR 1.35, 95%可信区间[1.04-1.75],P = 0.025)。结论:本研究结果表明,在接受肩袖修复的患者中,ARB的使用可能与较低的继发肩关节手术率有关,且主要见于男性患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JSES International
JSES International Medicine-Surgery
CiteScore
2.80
自引率
0.00%
发文量
174
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信